中山大学附属第六医院生殖医学研究中心 // 广东省生育力保存工程技术研究中心,广东 广州 510000
赵伟娥,博士,医师,研究方向:生殖内分泌,E-mail: zhaoweie3@mail.sysu.edu.cn
纸质出版日期:2023-01-20,
收稿日期:2022-08-03,
扫 描 看 全 文
赵伟娥,刘晓娉,陈攀宇等.多囊卵巢综合征患者基础LH升高对IVF-ET结局影响[J].中山大学学报(医学科学版),2023,44(01):78-84.
ZHAO Wei-e,LIU Xiao-ping,CHEN Pan-yu,et al.Effect of Elevated Basal LH on IVF-ET Outcomes in Patients with Polycystic Ovary Syndrome[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(01):78-84.
赵伟娥,刘晓娉,陈攀宇等.多囊卵巢综合征患者基础LH升高对IVF-ET结局影响[J].中山大学学报(医学科学版),2023,44(01):78-84. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20221113.001.
ZHAO Wei-e,LIU Xiao-ping,CHEN Pan-yu,et al.Effect of Elevated Basal LH on IVF-ET Outcomes in Patients with Polycystic Ovary Syndrome[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(01):78-84. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20221113.001.
目的
2
比较应用拮抗剂方案对多囊卵巢综合征(PCOS)不孕患者进行IVF-ET助孕治疗中,血清基础黄体生成素(LH)升高与LH正常两组患者的操作性促排卵结果及新鲜周期胚胎移植后妊娠结局的差异。
方法
2
回顾性分析2015年1月至2021年12月在中山大学附属第六医院生殖医学研究中心,行体外受精胚胎移植治疗的PCOS不孕患者的临床资料,根据其基础LH水平,将其分为LH升高组(LH≥10 U/L)与LH正常组(LH<10 U/L),其中升高组236例,正常组548例。比较两组患者的促排卵结果和新鲜周期胚胎移植的妊娠结局,包括:促性腺激素(Gn)启动剂量、Gn天数、Gn总量、获卵数、两原核(PN)率、可利用胚胎率、优质胚胎率、囊胚形成率、HCG阳性率、临床妊娠率、流产率、持续妊娠率和活产率;并分析两组促排卵过程中激素变化趋势的差异。
结果
2
与LH正常组比较,升高组Gn总剂量显著低于LH正常组(
P
<
0.001)。两组获卵数、2PN率、可利用胚胎率、优质胚胎率与囊胚形成率均无显著差异(
P
均
>
0.05);LH升高组的取消新鲜周期移植率及因预防OHSS而取消移植率与LH正常组比较差异无统计学意义(
P
均
>
0.05)。在新鲜移植周期中,LH升高组的HCG阳性率、临床妊娠率、流产率、持续妊娠率与活产率与LH正常组比较,均差异无统计学意义(
P
均
>
0.05)。
结论
2
PCOS不孕患者中,基础LH水平升高并不影响促排结果与新鲜胚胎移植的妊娠结局,促排卵治疗前是否需降低LH水平及基础LH水平升高患者是否需行全胚冷冻,还需要进一步研究。
Objective
2
To compare the outcomes in controlled ovarian stimulation (COH) and fresh embryo transfer between women with and those without a high basal luteinizing hormone (bLH) level in polycystic ovary syndrome (PCOS).
Methods
2
The clinical data of PCOS patients at the Reproductive Medicine Center of the Sixth Hospital of Sun Yat-sen University from January 2015 to December 2021 were retrospectively analyzed. They were divided into the high group (LH≥10 U/L) and normal group (LH<10 U/L) according to the bLH levels. The results of COH and pregnancy outcomes after fresh transfer were compared, including gonadotropin (Gn) initiation dose, Gn duration, total Gn dose, number of oocytes obtained, two pronuclei (2PN) rate, available embryos rate, high-quality embryos rate, blastocyst formation rate, human chorionic gonadotrophin (HCG) positive rate, clinical pregnancy rate (CPR), spontaneous abortion rate (SAR), ongoing pregnancy rate (OPR) and live birth rate (LBR). The differences in hormonal trends during COH were also analyzed.
Results
2
There were no statistically significant differences in age, body mass index, anti-Mullerian hormone, and type of infertility between the two groups. Compared with the normal group, the Gn initiation dose and Gn duration were not statistically significant (
P
>
0.05), while the total Gn dose was significantly lower (
P
<
0.001) in the high group. The number of oocytes retrieved, 2PN rate, available embryos rate, high-quality embryos rate, and blastocyst formation rate were comparable between the two groups (all
P
>
0.05). After fresh embryo transfer, they had similar pregnancy outcomes in the HCG positive rate, CPR, SAR, OPR and LBR (all
P
>
0.05).
Conclusions
2
In patients with PCOS, high bLH levels do not affect COH or pregnancy outcomes in fresh transfer cycles. Further studies are needed to determine whether LH levels need to be lowered prior to COH and whether frozen-all strategy is required in patients with elevated bLH levels.
多囊卵巢综合征黄体生成素拮抗剂方案
polycystic ovary syndromeluteinizing hormonegonadotropin-releasing hormone antagonist
Dovey S, McIntyre K, Jacobson D, et al. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles[J]. Fertil Steril, 2011, 96(3): 585-589.
Reichman DE, Zakarin L, Chao K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles[J]. Fertil Steril, 2014, 102(1): 99-102.
Barontini M, Garcia-Rudaz MC, Veldhuis JD. Mechanisms of hypothalamic-pituitary-gonadal disruption in polycystic ovarian syndrome[J]. Arch Med Res, 2001, 32(6): 544-552.
Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation[J]. Fertil Steril, 2002, 77(6): 1170-1177.
Su NJ, Huang CY, Liu J, et al. Association between baseline LH/FSH and live-birth rate after fresh-embryo transfer in polycystic ovary syndrome women[J]. Sci Rep, 2021, 11(1): 20490.
Ganor-Paz Y, Friedler-Mashiach Y, Ghetler Y, et al. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation[J]. J Endocrinol Invest, 2016, 39(7): 799-803.
Tarlatzis BC, Grimbizis G, Pournaropoulos F, et al. The prognostic value of basal luteinizing hormone: follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques[J]. Hum Reprod, 1995, 10(10): 2545-2549.
Orvieto R, Meltcer S, Liberty G, et al. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue?[J]. Gynecol Endocrinol, 2012, 28(6): 422-424.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004: 81(1): 19-25.
Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility, and miscarriage[J]. Lancet, 1990, 336(8724): 1141-1144.
Homburg R, Armar NA, Eshel A, et al. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome[J]. BMJ, 1988, 297(6655): 1024-1026.
Neeta S, Neha M, Yogita D. Do Basal Luteinizing hormone and luteinizing hormone/ follicle-stimulating hormone ratio have significance in prognosticating the outcome of in vitro fertilization cycles in polycystic ovary syndrome?[J]. J Hum Reprod Sci, 2021, 14(3): 326.
Tarlatzis BC, Grimbizis G. The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization[J]. J Assist Reprod Genet, 1997, 14(1): 1-4.
陈攀宇, 李满超, 孙鹏, 等. 小儿腹腔镜在青春期及青春期前重型地中海贫血患儿生育力保存中的应用及可行性分析[J]. 中山大学学报(医学科学版), 2022, 43(5): 764-771.
Chen PY, Li MC, Sun P, et al. Feasibility analysis and application of pediatric laparoscopy in the fertility preservation in pubertal and prepubertal patients with thalassemia major[J]. J Sun Yat-sen Univ(Med Sci), 2022, 43(5): 764-771.
郭映纯, 李婷婷, 朱婉珊, 等. 卵巢刺激和卵母细胞体外成熟在女性肿瘤患者生育力保存中的应用[J]. 中山大学学报(医学版), 2019, 40(1): 70-75.
Guo YC, Li TT, Zhu WS, et al. Ovarian stimulation and in vitro maturation for fertility preservation in female cancer patients[J]. J Sun Yat-sen Univ (Med Sci), 2019, 40(1): 70-75.
Wang J, Ding J, Qu B, et al. Does serum LH level influence IVF outcomes in women with PCOS undergoing GnRH-antagonist stimulation: a novel indicator[J]. J Clin Med, 2022, 11(16):4670.
Sun L, Ye J, Wang Y, et al. Elevated basal luteinizing hormone does not impair the outcome of human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles[J]. Sci Rep, 2018, 8(1): 13835.
Wei D, Shi Y, Li J, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome[J]. Hum Reprod, 2017, 32(2): 354-361.
Song SY, Yang JB, Song MS, et al. Effect of pretreatment with combined oral contraceptives on outcomes of assisted reproductive technology for women with polycystic ovary syndrome: a meta-analysis[J]. Arch Gynecol Obstet, 2019, 300(3): 737-750.
林海燕, 李予, 焦雪丹, 等. 基础LH水平过高患者拮抗剂方案中全程使用拮抗剂的效果观察[J]. 生殖医学杂志, 2020, 29(11): 1403-1409.
Lin HY, Li Y, Jiao XD, et al. Effect of using GnRH antagonist throughout course for antagonist protocol for patients with high basic LH level[J]. J Reprod Med, 2020, 29(11): 1403-1409.
Geng Y, Lai Q, Xun Y, et al. The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol[J]. Int J Gynaecol Obstet, 2018,142(1): 97-103.
Kolibianakis EM, Albano C, Camus M, et al. Relationship between LH and oestradiol in IVF cycles before GnRH antagonist initiation[J]. Reprod Biomed Online, 2003,7(2): 190-193.
李卓, 杨纨, 杨蕊, 等. 高雄激素血症对PCOS患者新鲜周期胚胎移植妊娠结局的影响[J/OL]. 中华生殖与避孕杂志, 2022, 42: 网络预发表. DOI: 10.3760/cma.j.cn101441-20220124-00037http://dx.doi.org/10.3760/cma.j.cn101441-20220124-00037.
Li Z, Yang W, Yang R, et al. Effect of hyperandrogenism on pregnancy outcomes of fresh cycle embryo transfer in patients with polycystic ovary syndrome[J/OL]. Chin J Reprod Contracep, 2022, 42: Epub ahead of print. DOI: 10.3760/cma.j.cn101441-20220124-00037http://dx.doi.org/10.3760/cma.j.cn101441-20220124-00037.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构